Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia

Buyse, Marc; Squifflet, Pierre; Lange, Beverly J.; Alonzo, Todd A.; Larson, Richard A.; Kolitz, Jonathan E.; George, Stephen L.; Bloomfield, Clara D.; Castaigné, Sylvie; Chevret, Sylvie; Blaise, Didier; Maraninchi, D; Lucchesi, Kathryn J.; Burzykowski, Tomasz

doi:10.1182/blood-2011-02-337725

Cited by 70 publications

(48 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the present time, maintenance chemotherapy is not part of standard AML treatment given a lack of convincing evidence of benefit. 168,169 Allogeneic HCT. AML is the most frequent indication for allogeneic HCT with a 10% annual increase in transplants performed worldwide.…”

Section: Intensive Postremission Therapymentioning

confidence: 99%

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Döhner

Estey

Grimwade

et al. 2017

Blood

Self Cite

4,685

5,387

View full text Add to dashboard Cite

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease

show abstract

Section: Intensive Postremission Therapymentioning

confidence: 99%

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Döhner

Estey

Grimwade

et al. 2017

Blood

Self Cite

4,685

5,387

View full text Add to dashboard Cite

show abstract

“…Importantly, as in Miller's study, both these groups administered cells following lymphodepleting chemotherapy and used low-dose IL-2 to achieve maximal in vivo donor NK cell expansion. However, recent data suggest that IL-2 alone is insufficient to induce leukemia control [102].…”

Section: Nk Cellsmentioning

confidence: 99%

Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment

et al. 2014

View full text Add to dashboard Cite

“…IL-2 alone was not found to be an effective remission maintenance therapy for AML patients in first CR (ref. 105 ). The combined immunotherapy of IL-2 with histamine dihydrochloride significantly improved leukemia free survival, but the overall survival was not improved 106 .…”

Section: Cytokines In Aml Therapymentioning

confidence: 99%

The role of cytokines in acute myeloid leukemia: A systematic review

Kupsa¹,

Horáček²,

Jebavý³

2012

BIOMED PAP

View full text Add to dashboard Cite

Background. Acute myeloid leukemia (AML) shows a high degree of heterogeneity owing to a variety of mutations and the mechanisms of leukemogenesis. This heterogeneity is often not reflected in standard treatment approaches which while providing predictable outcomes in the majority of patients fail in particular cases even with high-dose multiagent chemotherapy regimens. Further, the unselective effect of chemotherapy leads to high treatment-related toxicity and the enormous risk of infection during prolonged pancytopenia, preventing further dose escalation. Objectives. Cytokines play a role in leukemogenesis, AML cell persistence and treatment outcome. In this review we highlight cytokine dependent mechanisms essential for AML cell survival and the role of single cytokines in leukemogenesis and allogeneic transplantation-related phenomena. Cytokine-related mechanisms of leukemogenesis, AML cell persistence and resistance to chemotherapy are complex. Modulation of the cytokine network can disrupt signalling pathway activation and overcome the high resistance to treatment. It may also increase the selectivity of AML treatment, reduce the overall treatment-related toxicity and improve outcomes of AML treatment in all age groups of patients. Conclusions. This review provides a deeper insight into these processes with focus on the most vulnerable step. Special attention is paid to the possibility of selective influence on defined cell populations for therapeutic target. We believe that modulating cytokine-dependent processes in AML is an approach that could be included in standard chemotherapeutic regimens for improving overall treatment outcome.

show abstract

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia

Abstract: IL-2 is a natural, T cell-derived cytokine

Cited by 70 publications

References 45 publications

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment

The role of cytokines in acute myeloid leukemia: A systematic review

Contact Info

Product

Resources

About